Cencora, Inc.: Form 10-Q for the period ended Jun 30, 2019
Filed with the SEC on Aug 1, 2019 and accepted by EDGAR at Aug 1, 2019, 14:24 ET.
Management's discussion and analysis
As filed, 54,911 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Overview
The following discussion should be read in conjunction with the Consolidated Financial Statements and notes thereto contained herein and in conjunction with the financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended September 30, 2018.
We are one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health. We are organized based upon the products and services we provide to our customers. Our operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating segments that are not significant enough to require separate reportable segment disclosure, and, therefore, have been included in Other for the purpose of our reportable segment presentation.
Pharmaceutical Distribution Services Segment
The Pharmaceutical Distribution Services reportable segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. Through a number of operating businesses, the Pharmaceutical Distribution Services reportable segment provides pharmaceutical distribution (including plasma and other blood products, injectible pharmaceuticals, vaccines, and other specialty pharmaceutical products) and additional services to physicians who specialize in a variety of disease states, especially oncology, and to other healthcare providers, including hospitals and dialysis clinics. Additionally, the Pharmaceutical Distribution Services reportable segment provides data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The Pharmaceutical Distribution Services reportable segment also provides pharmacy management, staffing and additional consulting services, and supply management software to a variety of retail and institutional healthcare providers. Additionally, it delivers packaging solutions to institutional and retail healthcare providers.
Other
Other consists of operating segments that focus on global commercialization services and animal health (MWI Animal Health). The operating segments that focus on global commercialization services include AmerisourceBergen Consulting Services ("ABCS") and World Courier.
MWI Animal Health ("MWI") is a leading animal health distribution company in the United States and in the United Kingdom. MWI sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. Additionally, MWI offers demand-creating sales force services to manufacturers. ABCS, through a number of operating businesses, provides a full suite of integrated manufacturer services that range from clinical trial support to product post-approval and commercialization support. World Courier, which operates in over 50 countries, is a leading global specialty transportation and logistics provider for the biopharmaceutical industry.
Executive Summary
This executive summary provides highlights from the results of operations that follow:
- Revenue increased 4.9% and 7.5% from the prior year quarter and nine month period, respectively, primarily due to the revenue growth of our Pharmaceutical Distribution Services segment;
- Pharmaceutical Distribution Services' gross profit increased 4.9% and 6.5% from the prior year quarter and nine month period, respectively, due to the increase in revenue. The current year nine month period was also favorably impacted by the January 2018 consolidation of Profarma Distribuidora de Produtos Farmacêuticos S.A. ("Profarma"), a leading pharmaceutical wholesaler in Brazil (see Note 2 of the Notes to Consolidated Financial Statements), and the January 2018 acquisition of H.D. Smith, and was negatively impacted by our pharmaceutical compounding operations as production at the Memphis, Tennessee facility has been suspended since December 2017 (see Notes 5 and 13 of the Notes to Consolidated Financial Statements). Gross profit in Other increased 5.1% and 2.1% from the prior year quarter and nine month period, respectively. The increase in the current year quarter was primarily due to growth at MWI. The increase in the current year nine month period was primarily due to growth at World Courier, the January 2018 consolidation of the specialty joint venture in Brazil, and ABCS's growth in its Canadian operations, offset in part by lower gross profit at the Lash consulting group within ABCS. Total gross profit in the current year nine month period was favorably impacted by increases in gains from antitrust litigation settlements and last-in, first-out ("LIFO") credits in the current year period, and the reversal of a previously-estimated assessment related to the New York State Opioid Stewardship Act;
- Distribution, selling, and administrative expenses increased 4.9% and 7.7% from the prior year quarter and nine month period, respectively. The increase from the prior year quarter was primarily due to an increase in costs to support revenue growth. The increase in the nine month period was primarily due to the January 2018 consolidation of Profarma, the January 2018 acquisition of H.D. Smith, and due to an increase in costs to support the increase in revenue;
- Operating income increased 4.5% in the current year quarter primarily due to an increase in total segment operating income, offset in part by a decrease in gains from antitrust litigation settlements and a lower LIFO credit. Operating income decreased 27.7% in the current year nine month period primarily due to a $570.0 impairment of PharMEDium's long-lived assets (see Note 5 of the Notes to Consolidated Financial Statements), offset in part by increases in gains from antitrust litigation settlements, LIFO credits, and total operating segment income;
- Our effective tax rates were 18.6% and 12.2% for the quarter and nine month period ended June 30, 2019, respectively. Our effective tax rates were 19.5% and (33.4)% for the quarter and nine month period ended June 30, 2018, respectively. The effective tax rate in the nine month period ended June 30, 2019 was primarily impacted by the $570.0 million impairment of long-lived assets (see Note 5 of the Notes to Consolidated Financial Statements), which changed the mix of domestic and international income. The effective tax rate in the nine month period ended June 30, 2019 was also impacted by a $37.0 million decrease to the Company's transition tax related to the Tax Cuts and Jobs Act (the "2017 Tax Act"). The effective tax rate in the nine month period ended June 30, 2018 was primarily impacted by the effect of the 2017 Tax Act. Our effective tax rates for all periods reported herein were favorably impacted by the Company's international businesses in Switzerland and Ireland, which have lower income tax rates, and the benefit from stock option exercises and restricted stock vesting; and
- Net income and earnings per share were significantly lower in the current year nine month period primarily due to the $570.0 million impairment of long-lived assets and the significant income tax benefit recognized in the prior year nine month period as a result of the 2017 Tax Act.
Results of Operations
Revenue
(dollars in thousands)
| Three months ended June 30, 2019 | 2018 | Change | Nine months ended June 30, 2019 | 2018 | Change | |
|---|---|---|---|---|---|---|
| Pharmaceutical Distribution Services | $43,527,552 | $41,581,866 | 4.7% | $128,948,097 | $119,972,917 | 7.5% |
| Other: | ||||||
| MWI Animal Health | 1,021,936 | 945,342 | 8.1% | 2,923,813 | 2,836,917 | 3.1% |
| Global Commercialization Services | 712,602 | 651,881 | 9.3% | 2,147,092 | 1,899,635 | 13.0% |
| Total Other | 1,734,538 | 1,597,223 | 8.6% | 5,070,905 | 4,736,552 | 7.1% |
| Intersegment eliminations | (22,825) | (36,780) | (67,683) | (66,970) | ||
| Revenue | $45,239,265 | $43,142,309 | 4.9% | $133,951,319 | $124,642,499 | 7.5% |
We currently expect our revenue growth percentage to be in the mid-single digits in fiscal 2019. Our future revenue growth will continue to be affected by various factors, such as industry growth trends, including drug utilization, the introduction of new, innovative brand therapies (including biosimilars), the likely increase in the number of generic drugs that will be available over the next few years as a result of the expiration of certain drug patents held by brand-name pharmaceutical manufacturers and the rate of conversion from brand products to those generic drugs, price inflation and price deflation, general economic conditions in the United States, competition within the industry, customer consolidation, changes in pharmaceutical manufacturer pricing and distribution policies and practices, increased downward pressure on government and other third-party reimbursement rates to our customers, and changes in government rules and regulations.
Revenue increased by 4.9% and 7.5% from the prior year quarter and nine month period, respectively, primarily due to the revenue growth in our Pharmaceutical Distribution Services segment.
The Pharmaceutical Distribution Services segment's revenue grew by 4.7% and 7.5% from the prior year quarter and nine month period, respectively, primarily due to the growth of some of its largest customers, continued strong specialty product sales, and overall market growth. In addition, revenue increased in the current year nine month period due to the January 2018 consolidation of Profarma and the January 2018 acquisition of H.D. Smith.
Revenue in Other increased 8.6% and 7.1% from the prior year quarter and nine month period, respectively. The increase from the prior year quarter was primarily due to growth at MWI and ABCS's growth in its Canadian operations. The increase from the prior year nine month period was primarily due to ABCS's growth in its Canadian operations, growth at MWI, the January 2018 consolidation of the specialty joint venture in Brazil, and growth at World Courier.
A number of our contracts with customers, including group purchasing organizations, are typically subject to expiration each year. We may lose a significant customer if an existing contract with such customer expires without being extended, renewed, or replaced. During the nine months ended June 30, 2019, no significant contracts expired. Over the next twelve months, there are no significant contracts scheduled to expire. Additionally, from time to time, significant contracts may be terminated in accordance with their terms or extended, renewed, or replaced prior to their expiration dates. If those contracts are extended, renewed, or replaced at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.
Gross Profit
(dollars in thousands)
| Three months ended June 30, 2019 | 2018 | Change | Nine months ended June 30, 2019 | 2018 | Change | |
|---|---|---|---|---|---|---|
| Pharmaceutical Distribution Services | $904,124 | $862,291 | 4.9% | $2,774,689 | $2,606,008 | 6.5% |
| Other | 325,562 | 309,876 | 5.1% | 977,045 | 956,898 | 2.1% |
| Intersegment eliminations | (142) | (525) | (698) | (761) | ||
| Gain from antitrust litigation settlements | 3,480 | 35,600 | 142,735 | 35,938 | ||
| LIFO credit | 9,913 | 16,142 | 79,747 | 16,142 | ||
| PharMEDium remediation costs | (11,698) | (12,043) | (41,943) | (34,549) | ||
| New York State Opioid Stewardship Act | — | — | 22,000 | — | ||
| Gross profit | $1,231,239 | $1,211,341 | 1.6% | $3,953,575 | $3,579,676 | 10.4% |
Gross profit increased 1.6%, or $19.9 million, from the prior year quarter and 10.4%, or $373.9 million, from the prior year nine month period. Gross profit in the current year quarter was favorably impacted by the increase in Pharmaceutical Distribution Services' gross profit and the increase in gross profit in Other and was unfavorably impacted by lower gains from antitrust litigation settlements and a decrease in the LIFO credit. Gross profit in the current year nine month period was favorably impacted by the increase in Pharmaceutical Distribution Services' gross profit, the increase in gross profit in Other, an increase in gains from antitrust litigation settlements and the LIFO credit, and the reversal of a previously-estimated assessment related to the New York State Opioid Stewardship Act.
Our cost of goods sold for interim periods includes a LIFO provision that is recorded ratably on a quarterly basis and is based on our estimated annual LIFO provision. The annual LIFO provision, which we estimate on a quarterly basis, is affected by manufacturer pricing practices, which may be impacted by market and other external influences, expected changes in inventory quantities, and product mix, many of which are difficult to predict. Changes to any of the above factors may have a material impact to our annual LIFO provision. As of June 30, 2019, we reduced our estimate for generic deflation for fiscal 2019, which led to a reduction in the estimated annual LIFO credit.
After FDA inspections of our compounding facilities, we voluntarily suspended production activities in December 2017 at our largest compounding facility located in Memphis pending execution of certain remedial measures (see Notes 5 and 13 of the Notes to Consolidated Financial Statements). We continue to incur remediation costs in connection with our compounding operations. Additionally, in April 2019, we ceased production at our compounding facility in Cleveland, Mississippi.
New York State ("NYS") enacted the Opioid Stewardship Act ("OSA"), which went into effect on July 1, 2018. The OSA established an annual $100 million Opioid Stewardship Fund (the "Fund") and required manufacturers, distributors, and importers licensed in NYS to ratably source the Fund. The ratable share of the assessment for each licensee was to be based upon opioids sold or distributed to or within NYS. In September 2018, we accrued $22.0 million as an estimate of our liability under the OSA for the period from January 1, 2017 through September 30, 2018. In December 2018, the OSA was ruled unconstitutional by the U.S. District Court for the Southern District of New York, and, as a result, we reversed the $22.0 million accrual in the quarter ended December 31, 2018. NYS filed an appeal of the court decision on January 17, 2019; however, we do not believe a loss contingency is probable.
Pharmaceutical Distribution Services' gross profit increased 4.9%, or $41.8 million, from the prior year quarter and 6.5%, or $168.7 million, from the prior year nine month period. Gross profit in the current year quarter and nine month period increased due to the increase in revenue. Gross profit in the current year nine month period was also favorably impacted by the January 2018 consolidation of Profarma and the January 2018 acquisition of H.D. Smith and was negatively impacted by our pharmaceutical compounding operations as production at our Memphis facility has been suspended since December 2017. As a percentage of revenue, Pharmaceutical Distribution Services' gross profit margin of 2.08% and 2.15% in the quarter and nine month period ended June 30, 2019, respectively, increased 1 basis point from the prior year quarter and decreased 2 basis points from the nine month period. The decrease in gross profit margin from the nine month period was primarily due to increased sales to our larger customers, which typically have lower gross profit margins, and due to a lower contribution from our pharmaceutical compounding operations as it shipped fewer units primarily due to the suspension of production at our Memphis facility since December 2017 and the implementation of certain remedial measures at our operational PharMEDium locations, offset in part by the January 2018 consolidation of Profarma and the January 2018 acquisition of H.D. Smith.
Gross profit in Other increased 5.1%, or $15.7 million, and 2.1%, or $20.1 million, from the prior year quarter and nine month period, respectively. Gross profit in the current year quarter increased primarily due to growth at MWI. Gross profit in the current year nine month period increased primarily due to growth at World Courier, the January 2018 consolidation of the specialty joint venture in Brazil, and ABCS's growth in its Canadian operations, offset in part by lower gross profit at the Lash consulting group within ABCS. As a percentage of revenue, gross profit margin in Other of 18.77% in the quarter ended June 30, 2019 decreased from 19.40% in the prior year quarter. As a percentage of revenue, gross profit margin in Other of 19.27% in the nine month period ended June 30, 2019 decreased from 20.20% in the prior year period. The decrease in gross profit margin in the quarter and nine month period ended June 30, 2019 was primarily due to the decrease in gross profit at the Lash consulting group within ABCS.
We recognized gains from antitrust litigation settlements with pharmaceutical manufacturers of $3.5 million and $142.7 million during the quarter and nine month period ended June 30, 2019, respectively, compared to gains of $35.6 million and $35.9 million in the prior year quarter and nine month period, respectively. The gains were recorded as reductions to Cost of Goods Sold (see Note 11 of the Notes to Consolidated Financial Statements).
Operating Expenses
(dollars in thousands)
| Three months ended June 30, 2019 | 2018 | Change | Nine months ended June 30, 2019 | 2018 | Change | |
|---|---|---|---|---|---|---|
| Distribution, selling, and administrative | $656,943 | $626,548 | 4.9% | $1,941,564 | $1,802,496 | 7.7% |
| Depreciation and amortization | 107,596 | 120,045 | (10.4)% | 353,862 | 344,569 | 2.7% |
| Employee severance, litigation, and other | 60,006 | 75,553 | 156,067 | 143,023 | ||
| Impairment of long-lived assets | — | — | 570,000 | — | ||
| Total operating expenses | $824,545 | $822,146 | 0.3% | $3,021,493 | $2,290,088 | 31.9% |
Distribution, selling, and administrative expenses increased 4.9%, or $30.4 million, compared to the prior year quarter, and increased 7.7%, or $139.1 million, from the prior year nine month period. As a percentage of revenue, distribution, selling, and administrative expenses were 1.45% in the current and prior year periods. Pharmaceutical Distribution Services segment's expenses increased by 5.9% from the prior year quarter primarily due an increase in costs to support revenue growth. Pharmaceutical Distribution Services' expenses increased 10.9% from the prior year nine month period primarily due to an increase in costs to support revenue growth, the January 2018 consolidation of Profarma, and the January 2018 acquisition of H.D. Smith. Distribution, selling, and administrative expenses in Other increased 1.0% from the prior year quarter and were flat compared to the prior year nine month period as the reduction in operating expenses at the Lash consulting group was offset by the January 2018 consolidation of the specialty joint venture in Brazil.
Depreciation expense decreased 1.0% from the prior year quarter. Depreciation expense increased 5.8% from the prior year nine month period primarily due to the January 2018 acquisition of H.D. Smith and the January 2018 consolidation of Profarma. Amortization expense decreased 24.6% and 2.2% from the prior year quarter and nine month period, respectively. The decrease from the prior year quarter was primarily due to the impairment of PharMEDium intangible assets in March 2019 (see Note 5 of the Notes to Consolidated Financial Statements). The decrease from the prior year nine month period was primarily due to the impairment of PharMEDium intangible assets recorded in March 2019 and was largely offset by the amortization of intangible assets originating from our January 2018 acquisition of H.D. Smith and the January 2018 consolidation of Profarma.
Employee severance, litigation, and other in the quarter ended June 30, 2019 included $10.8 million of severance costs primarily related to PharMEDium restructuring activities and position eliminations resulting from our business transformation efforts and the integration of H.D. Smith, $18.8 million of litigation costs primarily related to legal fees in connection with opioid lawsuits and investigations, $12.3 million of acquisition-related deal and integration costs (primarily related to the integration of H.D. Smith), $16.3 million related to our business transformation efforts, and $1.8 million of other restructuring initiatives. Employee severance, litigation, and other in the quarter ended June 30, 2018 included $4.8 million of severance costs primarily related to position eliminations resulting from our business transformation efforts, $39.0 million of litigation costs primarily related to legal fees in connection with opioid lawsuits and investigations and related initiatives, $13.0 million related to our business transformation efforts, $9.7 million of other restructuring initiatives, and $9.0 million of acquisition-related deal and integration costs.
Employee severance, litigation, and other in the nine month period ended June 30, 2019 included $29.6 million of severance costs primarily related to PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D. Smith, and restructuring activities related to our consulting business, $47.2 million of litigation costs primarily related to legal fees in connection with opioid lawsuits and investigations, $34.3 million of acquisition-related deal and integration costs (primarily related to the integration of H.D. Smith), $33.1 million related to our business transformation efforts, and $11.8 million of other restructuring initiatives. Employee severance, litigation, and other in the nine month period ended June 30, 2018 included $33.2 million of severance costs primarily related to position eliminations resulting from our business transformation efforts, $49.5 million of litigation costs primarily related to legal fees in connection with opioid lawsuits and investigations and related initiatives, $23.7 million related to our business transformation efforts, $22.0 million of acquisition-related deal and integration costs, and $14.7 million of other restructuring initiatives.
We recorded a $570.0 million impairment of PharMEDium's long-lived assets in the nine months ended June 30, 2019 (see Note 5 of the Notes to Consolidated Financial Statements).
Operating Income
(dollars in thousands)
| Three months ended June 30, 2019 | 2018 | Change | Nine months ended June 30, 2019 | 2018 | Change | |
|---|---|---|---|---|---|---|
| Pharmaceutical Distribution Services | $411,707 | $392,652 | 4.9% | $1,301,948 | $1,269,940 | 2.5% |
| Other | 95,110 | 82,296 | 15.6% | 293,923 | 279,626 | 5.1% |
| Intersegment eliminations | (142) | (525) | (698) | (761) | ||
| Total segment operating income | 506,675 | 474,423 | 6.8% | 1,595,173 | 1,548,805 | 3.0% |
| Gain from antitrust litigation settlements | 3,480 | 35,600 | 142,735 | 35,938 | ||
| LIFO credit | 9,913 | 16,142 | 79,747 | 16,142 | ||
| PharMEDium remediation costs | (19,344) | (15,501) | (55,736) | (38,007) | ||
| New York State Opioid Stewardship Act | — | — | 22,000 | — | ||
| Acquisition-related intangibles amortization | (34,024) | (45,916) | (125,770) | (130,267) | ||
| Employee severance, litigation, and other | (60,006) | (75,553) | (156,067) | (143,023) | ||
| Impairment of long-lived assets | — | — | (570,000) | — | ||
| Operating income | $406,694 | $389,195 | 4.5% | $932,082 | $1,289,588 | (27.7)% |
Segment operating income is evaluated before gain from antitrust litigation settlements; LIFO credit; PharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation, and other; and impairment of long-lived assets.
Pharmaceutical Distribution Services' operating income increased 4.9%, or $19.1 million, and 2.5%, or $32.0 million, from the prior year quarter and nine month period, respectively, primarily due to the increase in gross profit, offset in part by an increase in operating expenses. As a percentage of revenue, Pharmaceutical Distribution Services' operating income margin increased 1 basis point from the prior year quarter and decreased 5 basis points from the prior year nine month period. The decrease in operating income margin from the prior year nine month period was primarily due to a lower contribution from our pharmaceutical compounding operations.
Operating income in Other increased 15.6%, or $12.8 million, and 5.1%, or $14.3 million, from the prior year quarter and nine month period, respectively, primarily due to the increase in gross profit.
We recorded a $13.7 million gain on the sale of an equity investment in Other (Income) Loss in the nine month period ended June 30, 2019.
We recorded a $30.0 million impairment of a non-customer note receivable related to a start-up venture in Other (Income) Loss in the nine months ended June 30, 2018.
Interest expense, net and the respective weighted average interest rates in the quarter ended June 30, 2019 and 2018 were as follows:
(dollars in thousands)
| 2019 Amount | Weighted Average Interest Rate | 2018 Amount | Weighted Average Interest Rate | |
|---|---|---|---|---|
| Interest expense | $48,710 | 3.73% | $52,845 | 3.64% |
| Interest income | (12,789) | 1.99% | (5,694) | 1.50% |
| Interest expense, net | $35,921 | $47,151 |
Interest expense, net and the respective weighted average interest rates in the nine month period ended June 30, 2019 and 2018 were as follows:
(dollars in thousands)
| 2019 Amount | Weighted Average Interest Rate | 2018 Amount | Weighted Average Interest Rate | |
|---|---|---|---|---|
| Interest expense | $147,828 | 3.74% | $140,212 | 3.55% |
| Interest income | (26,462) | 1.89% | (8,560) | 1.15% |
| Interest expense, net | $121,366 | $131,652 |
Interest expense, net decreased 23.8%, or $11.2 million, from the prior year quarter and decreased 7.8%, or $10.3 million, from the prior year nine month period. The decrease from the prior year quarter was driven by an increase in interest income due to a $1,057 million increase in our average invested cash balance during the current year quarter and an increase in interest rates. Additionally, interest expense was lower due to a decrease in average borrowings. The decrease from the prior year nine month period was due to an increase in interest income due to an $876 million increase in our average invested cash balance during the current year nine month period and an increase in interest rates, offset in part by an increase in interest expense due to the December 2017 issuance of senior notes to finance our January 2018 acquisition of H.D. Smith and the January 2018 consolidation of Profarma's debt and related interest expense.
For nine month period ended June 30, 2018, we recorded a $42.3 million loss in connection with the January 2018 consolidations of Profarma and the specialty joint venture in Brazil and a $23.8 million loss on the early retirement of our $400 million of 4.875% senior notes that were due in 2019. The loss on the early retirement of the debt included a $22.3 million prepayment premium and $1.5 million of an unamortized debt discount and unamortized debt issuance costs.
Our effective tax rates were 18.6% and 12.2% for the quarter and nine month period ended June 30, 2019, respectively. Our effective tax rates were 19.5% and (33.4)% for the quarter and nine month period ended June 30, 2018, respectively. The effective tax rate in the nine month period ended June 30, 2019 was primarily impacted by the $570.0 million impairment of long-lived assets (see Note 5 of the Notes to Consolidated Financial Statements), which changed the mix of domestic and international income. The effective tax rate in the nine month period ended June 30, 2019 was also impacted by a $37.0 million decrease to our transition tax related to the 2017 Tax Act. The effective tax rate in the nine month period ended June 30, 2018 was primarily impacted by the effect of the 2017 Tax Act. Our effective tax rates for all periods reported herein were favorably impacted by our international businesses in Switzerland and Ireland, which have lower income tax rates, and the benefit from stock option exercises and restricted stock vesting.
Net income and earnings per share were significantly lower in the current year nine month period primarily due to the $570.0 million impairment of long-lived assets and the significant income tax benefit recognized in the prior year nine month period as a result of the 2017 Tax Act.
Liquidity and Capital Resources
The following table illustrates our debt structure as of June 30, 2019, including availability under the multi-currency revolving credit facility, the receivables securitization facility, the revolving credit note, and the overdraft facility:
(in thousands)
| Fixed-Rate Debt: | Outstanding Balance | Additional Availability |
|---|---|---|
| $500,000, 3.50% senior notes due 2021 | $498,779 | $— |
| $500,000, 3.40% senior notes due 2024 | 497,621 | — |
| $500,000, 3.25% senior notes due 2025 | 496,141 | — |
| $750,000, 3.45% senior notes due 2027 | 742,889 | — |
| $500,000, 4.25% senior notes due 2045 | 494,460 | — |
| $500,000, 4.30% senior notes due 2047 | 492,422 | — |
| Capital lease obligations | 40 | — |
| Nonrecourse debt | 80,812 | — |
| Total fixed-rate debt | 3,303,164 | — |
| Variable-Rate Debt: | ||
| Revolving credit note | — | 75,000 |
| Term loan due 2020 | 399,710 | — |
| Overdraft facility due 2021 (£30,000) | 33,657 | 4,428 |
| Receivables securitization facility due 2021 | 350,000 | 1,100,000 |
| Multi-currency revolving credit facility due 2023 | — | 1,400,000 |
| Nonrecourse debt | 98,171 | — |
| Total variable-rate debt | 881,538 | 2,579,428 |
| Total debt | $4,184,702 | $2,579,428 |
Our operating results have generated cash flows, which, together with availability under our debt agreements and credit terms from suppliers, have provided sufficient capital resources to finance working capital and cash operating requirements, and to fund capital expenditures, acquisitions, repayment of debt, the payment of interest on outstanding debt, dividends, and repurchases of shares of our common stock.
Our primary ongoing cash requirements will be to finance working capital, fund the repayment of debt, fund the payment of interest on debt, fund repurchases of our common stock, fund the payment of dividends, finance acquisitions, and fund capital expenditures and routine growth and expansion through new business opportunities. Future cash flows from operations and borrowings are expected to be sufficient to fund our ongoing cash requirements.
As of June 30, 2019 and September 30, 2018, our cash and cash equivalents held by foreign subsidiaries were $660.9 million and $842.5 million, respectively, and are generally based in U.S. dollar denominated holdings. In the nine months ended June 30, 2019, we repatriated $350.0 million of cash held by foreign subsidiaries to use for general corporate purposes.
We have increased seasonal needs related to our inventory build during the December and March quarters that, depending on our cash balance, may require the use of our credit facilities to fund short-term capital needs. Our cash balance in the nine months ended June 30, 2019 and 2018 needed to be supplemented by intra-period credit facility borrowings to cover short-term working capital needs. The largest amount of intra-period borrowings under our revolving and securitization credit facilities that was outstanding at any one time during the nine months ended June 30, 2019 and 2018 was $240.6 million and $1,508.2 million, respectively. We had $573.7 million and $24,493.9 million of cumulative intra-period borrowings that were repaid under our credit facilities during the nine months ended June 30, 2019 and 2018, respectively.
We have a $1.4 billion multi-currency senior unsecured revolving credit facility ("Multi-Currency Revolving Credit Facility"), which was scheduled to expire in November 2021, with a syndicate of lenders. In October 2018, we entered into an amendment to, among other things, extend the maturity to October 2023 and modify certain restrictive covenants, including modifications to allow for indebtedness of foreign subsidiaries. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based on our debt rating and ranges from 70 basis points to 110 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee, as applicable (91 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee as of June 30, 2019) and from 0 basis points to 10 basis points over the alternate base rate and Canadian prime rate, as applicable. We pay facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based on our debt rating, ranging from 5 basis points to 15 basis points, annually, of the total commitment (9 basis points as of June 30, 2019). We may choose to repay or reduce our commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which we were compliant as of June 30, 2019.
We have a commercial paper program whereby we may from time to time issue short-term promissory notes in an aggregate amount of up to $1.4 billion at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase our borrowing capacity as it is fully backed by our Multi-Currency Revolving Credit Facility. There were no borrowings outstanding under our commercial paper program as of June 30, 2019.
We have a $1,450 million receivables securitization facility ("Receivables Securitization Facility"), which was scheduled to expire in November 2019. In October 2018, we entered into an amendment to extend the maturity date to October 2021. We have available to us an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters. Interest rates are based on prevailing market rates for short-term commercial paper or LIBOR plus a program fee. We pay a customary unused fee at prevailing market rates, annually, to maintain the availability under the Receivables Securitization Facility. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of June 30, 2019.
In April 2019, we elected to repay $150.0 million of our outstanding Receivables Securitization Facility balance prior to the scheduled maturity date.
We have an uncommitted, unsecured line of credit available to us pursuant to a revolving credit note ("Revolving Credit Note"). The Revolving Credit Note provides us with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million. The Revolving Credit Note may be decreased or terminated by the bank or us at any time without prior notice. We also have a £30 million uncommitted U.K. overdraft facility ("Overdraft Facility"), which expires in February 2021, to fund short term normal trading cycle fluctuations related to our MWI business.
In October 2018, we refinanced $400 million of outstanding term loans by issuing a new $400 million variable-rate term loan ("October 2018 Term Loan"), which matures in October 2020. The October 2018 Term Loan bears interest at a rate equal to a base rate or LIBOR, plus a margin of 65 basis points. The October 2018 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of June 30, 2019.
Nonrecourse debt is comprised of short-term and long-term debt belonging to the Brazil subsidiaries and is repaid solely from the Brazil subsidiaries' cash flows and such debt agreements provide that the repayment of the loans (and interest thereon) is secured solely by the capital stock, physical assets, contracts, and cash flows of the Brazil subsidiaries.
In November 2016, our board of directors authorized a share repurchase program allowing us to purchase up to $1.0 billion of outstanding shares of our common stock, subject to market conditions. During the nine months ended June 30, 2019, we purchased $125.8 million of our common stock under this program, which excluded $24.0 million of September 2018 purchases that cash settled in October 2018, to complete our authorization under this program.
In October 2018, our board of directors authorized a new share repurchase program allowing us to purchase up to $1.0 billion of outstanding shares of our common stock, subject to market conditions. During the nine months ended June 30, 2019, we purchased $373.0 million of our common stock, which included $0.1 million of June 2019 purchases that cash settled in July 2019. As of June 30, 2019, we had $627.0 million of availability remaining under this program.
We have market risk exposure to interest rate fluctuations relating to our debt. We manage interest rate risk by using a combination of fixed-rate and variable-rate debt. The amount of variable-rate debt fluctuates during the year based on our working capital requirements. We had $881.5 million of variable-rate debt outstanding as of June 30, 2019. We periodically evaluate financial instruments to manage our exposure to fixed and variable interest rates. However, there are no assurances that such instruments will be available in the combinations we want and/or on terms acceptable to us. There were no such financial instruments in effect as of June 30, 2019.
We also have market risk exposure to interest rate fluctuations relating to our cash and cash equivalents. We had $2,999.6 million in cash and cash equivalents as of June 30, 2019. The unfavorable impact of a hypothetical decrease in interest rates on cash and cash equivalents would be partially offset by the favorable impact of such a decrease on variable-rate debt. For every
$100 million of cash invested that is in excess of variable-rate debt, a 10 basis point decrease in interest rates would increase our annual net interest expense by $0.1 million.
We have minimal exposure to foreign currency and exchange rate risk from our non-U.S. operations. Our largest exposure to foreign exchange rates exists primarily with the Brazilian Real, the Euro, the U.K. Pound Sterling, and the Canadian Dollar. Revenue from our foreign operations is approximately two percent of our consolidated revenue. We may utilize foreign currency denominated forward contracts to hedge against changes in foreign exchange rates. We may use derivative instruments to hedge our foreign currency exposure, but not for speculative or trading purposes.
The following is a summary of our contractual obligations for future principal and interest payments on our debt, minimum rental payments on our noncancelable operating leases and financing obligations, and minimum payments on our other commitments as of June 30, 2019:
| Payments Due by Period (in thousands) | Debt, Including Interest Payments | Operating Leases | Financing Obligations 1 | Other Commitments | Total |
|---|---|---|---|---|---|
| Within 1 year | $287,386 | $95,058 | $22,364 | $85,630 | $490,438 |
| 1-3 years | 1,575,300 | 155,905 | 63,097 | 78,619 | 1,872,921 |
| 4-5 years | 709,143 | 119,065 | 71,823 | 58,444 | 958,475 |
| After 5 years | 3,310,663 | 180,337 | 279,076 | 105,444 | 3,875,520 |
| Total | $5,882,492 | $550,365 | $436,360 | $328,137 | $7,197,354 |
| 1 Represents the portion of future minimum lease payments relating to facility leases where we were determined to be the accounting owner (see Note 1 of the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended September 30, 2018 for a more detailed description of our accounting for leases). These payments are recognized as reductions to the financing obligation and as interest expense and exclude the future non-cash termination of the financing obligation. |
The 2017 Tax Act requires a one-time transition tax to be recognized on historical foreign earnings and profits. We expect to pay $182.6 million, net of overpayments and tax credits, related to the transition tax as of June 30, 2019, which is payable in installments over a six-year period commencing in January 2021. The transition tax commitment is included in "Other Commitments" in the above table.
Our liability for uncertain tax positions was $112.5 million (including interest and penalties) as of June 30, 2019. This liability represents an estimate of tax positions that we have taken in our tax returns which may ultimately not be sustained upon examination by taxing authorities. Since the amount and timing of any future cash settlements cannot be predicted with reasonable certainty, the estimated liability has been excluded from the above contractual obligations table.
During the nine months ended June 30, 2019, our operating activities provided cash of $1,671.2 million in comparison to $746.0 million in the prior year period. Cash provided by operations during the nine months ended June 30, 2019 was principally the result of an increase in accounts payable of $964.7 million, non-cash items of $957.2 million, and net income of $721.8 million, offset in part by an increases in accounts receivable of $672.7 million and inventories of $280.1 million. The increase in accounts payable was primarily driven by the increase in inventories and the timing of scheduled payments to suppliers. The non-cash items were comprised primarily of a $570.0 million impairment of PharMEDium's long-lived assets (see Note 5 of the Notes to Consolidated Financial Statements), $246.3 million of depreciation expense, and $137.8 million of amortization expense. The increase in accounts receivable was the result of our revenue growth and the timing of payments from our customers. The increase in our inventories as of June 30, 2019 reflects the increase in business volume.
We use days sales outstanding, days inventory on hand, and days payable outstanding to evaluate our working capital performance. The below financial metrics are calculated based upon a quarterly average and can be impacted by the timing of cash receipts and disbursements, which can vary significantly depending upon the day of the week in which the month ends.
| Three months ended June 30, 2019 | 2018 | Nine months ended June 30, 2019 | 2018 | |
|---|---|---|---|---|
| Days sales outstanding | 25.1 | 24.6 | 25.2 | 24.4 |
| Days inventory on hand | 28.0 | 28.7 | 28.6 | 30.5 |
| Days payable outstanding | 57.7 | 56.8 | 58.1 | 56.6 |
Our days inventory on hand in the nine months ended June 30, 2018 were higher than the current year nine month period primarily due to the prior year onboarding of new business with our largest customer.
Our cash flows from operating activities can vary significantly from period to period based upon fluctuations in our period-end working capital account balances. Additionally, any changes to payment terms with a significant customer or manufacturer supplier could have a material impact to our cash flows from operations. Operating cash flows during the nine months ended June 30, 2019 included $137.6 million of interest payments and $94.3 million of income tax payments, net of refunds. Operating cash flows during the nine months ended June 30, 2018 included $129.0 million of interest payments and $93.2 million of income tax payments, net of refunds.
During the nine months ended June 30, 2018, our operating activities provided $746.0 million of cash. Cash provided by operations during the nine months ended June 30, 2018 was principally the result of net income of $1,421.9 million, an increase in accounts payable of $463.9 million, and an increase in income taxes payable of $269.5 million, offset in part by an increase in accounts receivable of $1,107.6 million and negative non-cash items of $241.2 million. The increase in accounts payable was primarily driven by the timing of scheduled payments to suppliers. The increase in income taxes payable was primarily driven by a one-time transition tax on historical foreign earnings and profits through December 31, 2017 in connection with tax reform. The increase in accounts receivable was the result of our revenue growth and the timing of payments from our customers. The non-cash items were comprised primarily of a $747.4 million deferred income tax benefit, $233.5 million of depreciation expense, and $149.1 million of amortization expense. The deferred income tax benefit was primarily the result of applying a lower U.S. federal income tax rate to net deferred tax liabilities as of December 31, 2017 in connection with tax reform.
Capital expenditures for the nine months ended June 30, 2019 and 2018 were $230.8 million and $248.4 million, respectively. Significant capital expenditures in the nine months ended June 30, 2019 included costs associated with the construction of a new support facility and technology initiatives, including costs related to enhancing and upgrading our information technology systems. We currently expect to invest approximately $300 million for capital expenditures during fiscal 2019. Significant capital expenditures in the nine months ended June 30, 2018 included technology initiatives, including costs related to enhancing and upgrading our information technology systems and costs associated with expanding distribution capacity.
We acquired businesses to support our animal health business for $54.0 million and $70.0 million in the nine months ended June 30, 2019 and 2018, respectively. In the nine months ended June 30, 2018, we also acquired H.D. Smith, the largest independent pharmaceutical wholesaler in the United States, for $815.0 million. In addition, we made incremental investments in Brazil totaling $78.1 million. The cash used on the above investments was offset by $179.6 million of cash consolidated in connection with the Brazil investments (see Note 2 of the Notes to Consolidated Financial Statements).
Net cash used in financing activities in the nine months ended June 30, 2019 principally resulted from $522.8 million in purchases of our common stock and $255.1 million in cash dividends paid on our common stock. Net cash provided by financing activities in the nine months ended June 30, 2018 principally resulted from the issuance of $750 million of 3.45% senior notes and the issuance of $500 million of 4.30% senior notes, offset in part by the early retirement of $400 million of 4.875% senior notes.
In November 2018, our board of directors increased the quarterly cash dividend by 5% from $0.38 per share to $0.40 per share. We anticipate that we will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remains within the discretion of our board of directors and will depend upon our future earnings, financial condition, capital requirements, and other factors.
Cautionary Note Regarding Forward-Looking Statements
Certain of the statements contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this report are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as "expect," "likely," "outlook," "forecast," "would," "could," "should," "can," "project," "intend," "plan," "continue," "sustain," "synergy," "on track," "believe," "seek," "estimate," "anticipate," "may," "possible," "assume," variations of such words, and similar expressions are intended to identify such forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. Among the factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in pharmaceutical market growth rates; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; increased public concern over the abuse of opioid medications; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; material adverse developments or resolution of pending legal proceedings; the retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. and the Company, including principally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our compounded sterile preparations (CSP) business or the related consent decree; suspension of production of CSPs, including continued suspension at our Memphis facility; managing foreign expansion, including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market volatility and disruption; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; the loss, bankruptcy or insolvency of a major supplier; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the Company’s operations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations or PharMEDium), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, including the integration of H. D. Smith and PharMEDium, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the fact that the acquisition of H. D. Smith may make it more difficult to establish or maintain relationships with employees, suppliers, customers and other business partners; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) elsewhere in this report, (ii) in Item 1A (Risk Factors), in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2018 and elsewhere in that report and (iii) in other reports filed by the Company pursuant to the Securities Exchange Act. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.
Market risk
As filed, 262 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company’s most significant market risks are the effects of changing interest rates, foreign currency risk, and changes in the price and volatility of the Company’s common stock. See the discussion under "Liquidity and Capital Resources" in Item 2 on page 29.
Controls and procedures
As filed, 1,359 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
The Company maintains disclosure controls and procedures that are intended to ensure that information required to be disclosed in the Company’s reports submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. These controls and procedures also are intended to ensure that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.
The Company’s Chief Executive Officer and Chief Financial Officer, with the participation of other members of the Company’s management, have evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a — 15(e) and 15d — 15(e) under the Exchange Act) and have concluded that the Company’s disclosure controls and procedures were effective for their intended purposes as of the end of the period covered by this report.
Changes in Internal Control over Financial Reporting
During the third quarter of fiscal 2019, there was no change in AmerisourceBergen Corporation’s internal control over financial reporting that materially affected, or is reasonably likely to materially affect, internal control over financial reporting.
Risk factors
As filed, 141 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Our significant business risks are described in Item 1A to Form 10-K for the year ended September 30, 2018 to which reference is made herein.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-04-01 to 2019-06-30 | $45.24bn | us-gaap:Revenues |
| Revenue | 9 months2018-10-01 to 2019-06-30 | $133.95bn | us-gaap:Revenues |
| Cost of revenue | 3 months2019-04-01 to 2019-06-30 | $44.01bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2018-10-01 to 2019-06-30 | $130.00bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2019-04-01 to 2019-06-30 | $1.23bn | us-gaap:GrossProfit |
| Gross profit | 9 months2018-10-01 to 2019-06-30 | $3.95bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2019-04-01 to 2019-06-30 | $656.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2018-10-01 to 2019-06-30 | $1.94bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2019-04-01 to 2019-06-30 | $406.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2018-10-01 to 2019-06-30 | $932.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2019-04-01 to 2019-06-30 | $69.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2018-10-01 to 2019-06-30 | $100.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-04-01 to 2019-06-30 | $302.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2018-10-01 to 2019-06-30 | $722.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-04-01 to 2019-06-30 | $1.43 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2018-10-01 to 2019-06-30 | $3.42 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-04-01 to 2019-06-30 | $1.44 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2018-10-01 to 2019-06-30 | $3.45 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-04-01 to 2019-06-30 | 211,161,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2018-10-01 to 2019-06-30 | 211,151,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2018-10-01 to 2019-06-30 | $1.67bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2018-10-01 to 2019-06-30 | $230.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2018-10-01 to 2019-06-30 | $255.1m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months2018-10-01 to 2019-06-30 | $522.8m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Current assets | At period end2019-06-30 | $27.40bn | us-gaap:AssetsCurrent |
| Total assets | At period end2019-06-30 | $38.48bn | us-gaap:Assets |
| Current liabilities | At period end2019-06-30 | $28.79bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2019-06-30 | $4.02bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2019-06-30 | $33.7m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2019-06-30 | $2.99bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001140859-19-000029. Last ingested by Listed: Nov 15, 2026, 01:23 ET. Listed shows no prices and gives no investment advice.